Clinical Trial: Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Effect of Second-line Irinotecan and Capecitabine Versus Irinotecan Alone in Advanced Biliary Tract Cancer Patients Progressed After First-line Gemcitabine and Cisplatin: A Randomized Controlled Study

Brief Summary: This study is designed to investigate the effect of second-line irinotecan and capecitabine versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract cancer patients.

Detailed Summary:
Sponsor: Zhejiang University

Current Primary Outcome: Progression Free Survival [ Time Frame: within 1 year ]

PFS


Original Primary Outcome: Same as current

Current Secondary Outcome: Overall Survival [ Time Frame: within 1 year ]

OS


Original Secondary Outcome: Same as current

Information By: Zhejiang University

Dates:
Date Received: September 21, 2015
Date Started: September 2015
Date Completion: December 2017
Last Updated: November 29, 2015
Last Verified: November 2015